Jeff Yass’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-106,400
| Closed | -$1.06M | – | 13148 |
|
|
2025
Q2 | $1.06M | Buy |
+106,400
| New | +$857K | ﹤0.01% | 7260 |
|
|
2025
Q1 | – | Sell |
-71,000
| Closed | -$545K | – | 12966 |
|
|
2024
Q4 | $545K | Sell |
71,000
-34,500
| -33% | -$296K | ﹤0.01% | 8459 |
|
|
2024
Q3 | $1.08M | Sell |
105,500
-73,000
| -41% | -$1.11M | ﹤0.01% | 6619 |
|
|
2024
Q2 | $2.65M | Buy |
178,500
+153,700
| +620% | +$2.2M | ﹤0.01% | 4541 |
|
|
2024
Q1 | $338K | Sell |
24,800
-82,600
| -77% | -$900K | ﹤0.01% | 9434 |
|
|
2023
Q4 | $1.18M | Sell |
107,400
-2,800
| -3% | -$27.8K | ﹤0.01% | 6591 |
|
|
2023
Q3 | $1.21M | Buy |
+110,200
| New | +$1.41M | ﹤0.01% | 6216 |
|
|
2023
Q2 | – | Sell |
-22,300
| Closed | -$304K | – | 12601 |
|
|
2023
Q1 | $304K | Buy |
+22,300
| New | +$400K | ﹤0.01% | 9693 |
|
|
2022
Q3 | – | Sell |
-47,600
| Closed | -$981K | – | 13650 |
|
|
2022
Q2 | $981K | Buy |
47,600
+37,800
| +386% | +$897K | ﹤0.01% | 6579 |
|
|
2022
Q1 | $315K | Buy |
+9,800
| New | +$356K | ﹤0.01% | 10153 |
|
Other funds holding ITOS
Jeff Yass's ITOS Position: Q3 2025 in Review
Jeff Yass sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 144,080 shares — an estimated $1.44M sold.
Jeff Yass first reported a position in ITOS in Q1 2021 and held it in 17 quarters. The position peaked at $3.58M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Jeff Yass reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Jeff Yass sold 144,080 iTeos Therapeutics shares in Q3 2025, an estimated $1.44M.
- Jeff Yass first reported a position in iTeos Therapeutics in Q1 2021 and held it in 17 quarters.
- Jeff Yass's iTeos Therapeutics position peaked at $3.58M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.